PERRIGO Co plc (PRGO) Form 8-K — Aug 5, 2026

Key figures

Eps

$0.63 reported diluted (continuing ops); $0.50 All In adjusted diluted; $0.46 Core adjusted diluted

Revenue

$1,022.8 million All In reported net sales; Core net sales $906.7 million

Guidance

FY2026 reaffirmed: All In net sales growth (5.5)% to (1.5)%; Core organic (3.5)% to +0.5%; All In adjusted EPS $2.00-$2.30; Core adjusted EPS $2.25-$2.55; net interest expense ~$156 million; adjusted effective tax rate ~18.0%

Net Income

$74.5 million Q2 net income; $(324.1) million six-month net loss

Total Debt

approximately $3.3 billion

Revenue Yoy

-3.2% All In reported; -3.1% Core reported; -1.3% All In organic; -3.5% Core organic

Total Assets

$7,609.5 million

Cash Position

$399.7 million

Q2 capex

$14 million

Net leverage

approximately 4.0x adjusted EBITDA

Self care net sales

$577 million (-3.7% YoY)

Q2 dividends returned

$40 million

Q2 operating cash flow

$83 million

Ytd impairment charges

$331.8 million

Dermacosmetics proceeds

approximately $359 million applied largely to debt reduction

Infant formula net sales

$101 million (+23.1% YoY)

Specialty care net sales

$227 million (-2.8% YoY)

Core adjusted gross margin

37.0% (down 250 bps)

Gain on dermacosmetics sale

$129.4 million pre-tax

All in reported gross margin

30.7% (down 370 bps)

Core organic net sales change

-3.5%

Six month operating cash flow

$(31.0) million

Core adjusted operating margin

13.0% (down 160 bps)

Adjusted weighted average shares

approximately 139.3 million

Fy26 under absorption eps headwind

approximately $0.60 ($0.26 recognized in Q1, $0.18 in Q2)

Price after filing

Close on the filing date to close N calendar days later (from $10.78). Historical, not a forecast.